9 results on '"Peter Ping Lin"'
Search Results
2. Data from Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance
- Author
-
Lin Shen, Min Li, Peter Ping Lin, Xiaojuan Wang, Yanyan Li, Zhi Peng, Shan Li, Daisy Dandan Wang, Jifang Gong, Dan Liu, Xiaotian Zhang, and Yilin Li
- Abstract
Purpose: Previous human epidermal growth factor receptor-2 (HER2)-derived resistance studies were based on ex vivo models, which could not mirror evolutionary expression of HER2 during therapy. To investigate dynamic expression of HER2 and its contribution to developing therapeutic resistance conferred by chromosome aneuploidy, both the HER2 phenotype and chromosome 8 (Chr 8) aneuploidy on circulating tumor cells (CTC) were coexamined in advanced gastric cancer (AGC) patients.Experimental Design: A total of 115 AGC patients, including 56 of histopathologic HER2+ (hHER2+) subjects who received first-line HER2-targeted therapy plus chemotherapy, and 59 of hHER2− patients who received chemotherapy alone, were prospectively enrolled. Both HER2 phenotype and Chr8 aneuploidy of CTCs in patients were coexamined by HER2-iFISH during therapy.Results: A fluctuated positive HER2 phenotype on CTCs (cHER2+) was revealed, showing cHER2+ at different time intervals during treatment. Acquisition of the cHER2+ phenotype in 91.0% of hHER2+ and 76.2% hHER2− patients was demonstrated to correlate with development of resistance to trastuzumab-targeted therapy for hHER2+ patients and chemotherapy alone for hHER2− patients. Aneuploid Chr8 was demonstrated to participate in the acquisition of the cHER2+ phenotype, which provides a growth advantage to HER2+ CTCs against therapeutic pressure, leading to the development of therapeutic resistance.Conclusions: Compared with low positivity of conventional histopathologic hHER2 examination routinely performed once, significant higher positivity of cHER2+ on CTCs was observed. Continuously examining cHER2 shows unique advantages with respect to monitoring therapeutic resistance in real time in carcinoma patients. Moreover, contribution of chromosome aneuploidy to the phenotypic evolution of HER2 expression on CTCs may help elucidate underlying mechanisms of developing therapeutic resistance. Clin Cancer Res; 24(21); 5261–71. ©2018 AACR.
- Published
- 2023
3. Case report: Post-therapeutic laryngeal carcinoma patient possessing a high ratio of aneuploid CTECs to CTCs rapidly developed de novo malignancy in pancreas
- Author
-
Jiaoping Mi, Fang Yang, Jiani Liu, Mingyang Liu, Alexander Y. Lin, Daisy Dandan Wang, Peter Ping Lin, and Qi Zeng
- Subjects
Cancer Research ,Oncology - Abstract
Effectively evaluating therapeutic efficacy, detecting minimal residual disease (MRD) after therapy completion, and predicting early occurrence of malignancy in cancer patients remain as unmet imperative clinical demands. This article presents a case of a laryngeal carcinoma patient who had a surgical resection and complete post-operative chemoradiotherapy in combination with the targeted therapy, then rapidly developed pancreatic adenocarcinoma. Detected by SE-iFISH, the patient had a substantial amount of 107 non-hematological aneuploid circulating rare cells including 14 circulating tumor cells (CTCs, CD31-/CD45-) and 93 circulating tumor endothelial cells (CTECs, CD31+/CD45-) with a high ratio of CTECs/CTCs > 5 upon finishing post-surgical combination regimens. Positive detection of those aneuploid non-hematological circulating rare cells was five months prior to subsequent plasma CA19-9 increasing and ten months before the de novo pancreatic cancer was diagnosed by medical imaging modalities. Besides previously reported clinical utilities of co-detection of aneuploid CD31- CTCs and CD31+ CTECs in real-time evaluation of therapeutic efficacy, longitudinal monitoring of emerging treatment resistance and adequate detection of MRD, a large cohort study is necessary to further investigate whether, and how, a high ratio of MRD CTECs to CTCs may function as an appropriate index forecasting either occurrence or metastatic distant recurrence of malignancy in post-therapeutic cancer patients.
- Published
- 2022
4. Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas
- Author
-
Mingxiao Li, Faliang Gao, Xiaohui Ren, Gehong Dong, Hongyan Chen, Alexander Y. Lin, Daisy Dandan Wang, Mingyang Liu, Peter Ping Lin, Shaoping Shen, Haihui Jiang, Chuanwei Yang, Xiaokang Zhang, Xuzhe Zhao, Qinghui Zhu, Ming Li, Yong Cui, and Song Lin
- Subjects
Cancer Research ,Endothelial Cells ,General Medicine ,Glioma ,Aneuploidy ,Neoplastic Cells, Circulating ,Prognosis ,ErbB Receptors ,Oncology ,Drug Resistance, Neoplasm ,Glial Fibrillary Acidic Protein ,Biomarkers, Tumor ,Humans ,In Situ Hybridization, Fluorescence - Abstract
Aneuploidy is the hallmark of malignancy. Our previous study successfully detected nonhematogenic circulating aneuploidy cells (CACs) in types of gliomas. The current prospective clinical study aims to further precisely subcategorize aneuploid CACs, including CD31
- Published
- 2022
5. Longitudinal Detection of CD44v6 Circulating Tumor Cells Facilitates Risk Stratification of Small-Cell Lung Cancer: A Prospective, Non-Interventional, Multi-Center Study
- Author
-
Ying Wang, Lina Zhang, Zhiyun Zhang, Yanxia Liu, Xingsheng Hu, Baohua Lu, Yuan Gao, Li Tong, Zan Liu, Hongxia Zhang, Peter Ping Lin, Baolan Li, Olivier Gires, and Tongmei Zhang
- Subjects
History ,Polymers and Plastics ,Business and International Management ,Industrial and Manufacturing Engineering - Published
- 2022
6. Aneuploid Circulating Tumor Cells as a Predictor of Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer
- Author
-
Fangliang Lu, Daisy Dandan Wang, Chao Lv, Peter Ping Lin, Shanyuan Zhang, Miao Huang, Yuanyuan Ma, Yue Yang, and Shaolei Li
- Subjects
Oncology ,Cisplatin ,Chemotherapy ,medicine.medical_specialty ,business.industry ,Surrogate endpoint ,medicine.medical_treatment ,therapeutic response ,Tumor Cell Necrosis ,Aneuploidy ,International Journal of General Medicine ,General Medicine ,medicine.disease ,circulating tumor cell ,Circulating tumor cell ,non-small-cell lung cancer ,Response Evaluation Criteria in Solid Tumors ,Internal medicine ,medicine ,Lung cancer ,business ,medicine.drug ,Original Research ,neoadjuvant chemotherapy - Abstract
Miao Huang,1,* Yuanyuan Ma,1,* Chao Lv,1 Shaolei Li,1 Fangliang Lu,1 Shanyuan Zhang,1 Daisy Dandan Wang,2 Peter Ping Lin,2 Yue Yang1 1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute, Beijing, Peopleâs Republic of China; 2Department of Oncology, Cytelligen, San Diego, CA, USA*These authors contributed equally to this workCorrespondence: Yue YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian District, Beijing, 100142, Peopleâs Republic of ChinaTel +86 10 8819 6568Email yangyue236@outlook.comPurpose: This study aimed to explore the potential application of circulating tumor cells (CTCs) in predicting the therapeutic effect of neoadjuvant chemotherapy (NAC) in non-small-cell lung cancer (NSCLC).Methods: Using integrated subtraction enrichment and immunostaining-fluorescence in situ hybridization, the serial CTCs of patients with NSCLC were detected in 7.5 mL of blood at baseline and after two cycles of cisplatin-based NAC, and all aneuploidies of chromosome 8 were examined in the enriched CTCs. Tumor responses were evaluated radiologically with serial chest computed tomography (CT) using the response evaluation criteria in solid tumors and microscopically using the tumor cell necrosis rate (TCNR) of the resected specimen after NAC.Results: After two cycles of cisplatin-based NAC, 89% (8/9) of the patients with radiological partial response to NAC had reduced CTC numbers, while 73% (8/11) of the patients with stable disease exhibited increased CTC numbers (P = 0.0098). On pathological examination, 90% (9/10) of patients with a TCNR lower than 30% had > 1 CTC post-NAC, while 80% (4/5) of patients with a TCNR higher than 30% had ⤠1 CTC post-NAC (P = 0.017). In aneuploidy analysis, the positive rate (CTC > 0) of triploid CTCs was found to have increased after NAC, in contrast with the tetraploid and multiploid CTCs. Furthermore, tetraploid and multiploid CTCs were found to be significantly downregulated in the patients with partial response to NAC.Conclusion: The correlations of aneuploid CTCs with both radiological and pathological responses in patients with NSCLC who received NAC were summarized, and the findings indicate that enumerating and karyotyping aneuploid CTCs can serve as a surrogate marker for disease monitoring in NSCLC.Keywords: non-small-cell lung cancer, circulating tumor cell, neoadjuvant chemotherapy, therapeutic response
- Published
- 2021
7. Small Cell Size Circulating Aneuploid Cells as a Biomarker of Prognosis in Resectable Non-Small Cell Lung Cancer
- Author
-
Jianzhi Zhang, Yang Hong, Jian Fang, Chao Lv, Peter Ping Lin, Jiahui Si, Yue Yang, Ying Xiong, Yuanyuan Ma, and Jie Zhang
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Biology ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,circulating aneuploid cells ,medicine ,Clinical significance ,cardiovascular diseases ,resection ,Stage (cooking) ,Lung cancer ,non-small cell lung cancer ,Original Research ,medicine.diagnostic_test ,Large cell ,nutritional and metabolic diseases ,Karyotype ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,030104 developmental biology ,030220 oncology & carcinogenesis ,Biomarker (medicine) ,biomarker ,prognosis ,Immunostaining ,Fluorescence in situ hybridization - Abstract
ObjectiveThe size distribution of circulating aneuploid cells (CACs) and its clinical significance were investigated in resectable non-small cell lung cancer (NSCLC).Patients and MethodsA total of 50 patients with resectable NSCLC were enrolled in this study. Blood samples (50 pre-surgery and 35 post-surgery) were collected and used for the detection of CAC chromosome 8 heteroploidy through the subtraction enrichment and immunostaining fluorescence in situ hybridization (SE-iFISH) method.ResultsLess than 20% small cell size and more than 80% large cell size CACs were detected. Karyotypes, including triploid, tetraploid, and multiploid, had varying distributions. The triploid subtype accounted for the majority of small cell size CACs, whereas the multiploid subtype accounted for the majority of large cell size CACs. We found that total small cell size and triploid small cell size CACs, but not large cell size CACs, derived from pre-surgery samples, were associated with shorter disease-free survival. Moreover, total small cell size and triploid small cell size CACs were associated with higher TNM stage and recurrence. Nevertheless, the variation between pre- and post-surgery CACs was not related to survival among patients with resectable NSCLC.ConclusionsPre-surgery small cell size CACs, especially the triploid subtype, could be regarded as a potential prognostic biomarker for patients with resectable NSCLC.
- Published
- 2020
8. PD-L1
- Author
-
Lina, Zhang, Xinyong, Zhang, Yanxia, Liu, Tongmei, Zhang, Ziyu, Wang, Meng, Gu, Yilin, Li, Daisy Dandan, Wang, Weiying, Li, and Peter Ping, Lin
- Subjects
Male ,Neovascularization, Pathologic ,Programmed Cell Death 1 Receptor ,Endothelial Cells ,Middle Aged ,Aneuploidy ,Neoplastic Cells, Circulating ,B7-H1 Antigen ,Progression-Free Survival ,Nivolumab ,Drug Resistance, Neoplasm ,Carcinoma, Non-Small-Cell Lung ,Biomarkers, Tumor ,Disease Progression ,Tumor Microenvironment ,Humans ,Female ,Immunotherapy - Abstract
Sustained angiogenesis and increased PD-L1 expression on endothelial and carcinoma cells contribute toward fostering an immunosuppressive microenvironment suitable for tumor growth. PD-L1
- Published
- 2019
9. Quantified postsurgical small cell size CTCs and EpCAM
- Author
-
Liang, Wang, Yilin, Li, Jing, Xu, Aiqun, Zhang, Xuedong, Wang, Rui, Tang, Xinjing, Zhang, Hongfang, Yin, Manting, Liu, Daisy Dandan, Wang, Peter Ping, Lin, Lin, Shen, and Jiahong, Dong
- Subjects
Adult ,Chromosome Aberrations ,Male ,Carcinoma, Hepatocellular ,Liver Neoplasms ,Neoplastic Stem Cells ,Humans ,Female ,Middle Aged ,Neoplasm Recurrence, Local ,Epithelial Cell Adhesion Molecule ,Neoplastic Cells, Circulating ,Aged - Abstract
Detection of hepatocellular carcinoma circulating tumor cells performed with conventional strategies, is significantly limited due to inherently heterogeneous and dynamic expression of EpCAM, as well as degradation of cytokeratins during epithelial-to-mesenchymal transition, which inevitably lead to non-negligible false negative detection of such "uncapturable and invisible" CTCs. A novel SE-iFISH strategy, improved for detection of HCC CTCs in this study, was applied to comprehensively detect, in situ phenotypically and karyotypically characterize hepatocellular and cholangiocarcinoma CTCs (CD45
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.